CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top winning strategies
3.2.1.1. Competitive intelligence of companies and their strategies
3.2.2. Top investment pockets
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of competitive rivalry
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Rise in geriatric population and favorable demographics
3.4.1.2. Growth in incidence of diabetes, obesity, and chronic conditions
3.4.1.3. Technological advancements to deal with complex wounds
3.4.1.4. Increase in awareness to reduce healthcare costs
3.4.2. Restraints
3.4.2.1. Reluctance in adoption of new technologies
3.4.3. Opportunities
3.4.3.1. Increase in focus towards advanced treatment protocols
3.4.3.2. Significant unmet needs in wound care
CHAPTER 4 PHILIPPINES WOUND CARE MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ADVANCED WOUND CARE
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.3.1. Market by infection management
4.2.3.1.1. Market size and forecast
4.2.3.1.1.1. Silver wound dressings
4.2.3.1.1.2. Non-silver dressings
4.2.3.1.1.3. Collagen dressings
4.2.3.2. Market by exudate management
4.2.3.2.1. Market size and forecast
4.2.3.2.1.1. Hydrocolloid dressings
4.2.3.2.1.2. Foam dressings
4.2.3.2.1.3. Alginate dressings
4.2.3.2.1.4. Hydrogel dressings
4.2.3.3. Market by active wound care
4.2.3.3.1. Market size and forecast
4.2.3.3.1.1. Skin substitutes
4.2.3.3.1.2. Growth factors
4.2.3.4. Market by therapy device
4.2.3.4.1. Market size and forecast
4.2.3.4.1.1. Negative pressure wound therapy (NPWT)
4.2.3.4.1.2. Oxygen & hyperbaric oxygen equipment
4.2.3.4.1.3. Electromagnetic therapy devices
4.2.3.4.1.4. Others
4.3. SURGICAL WOUND CARE
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.3.1. Market by sutures & staples
4.3.3.1.1. Market size and forecast
4.3.3.2. Market by tissue adhesives, sealants, & glues
4.3.3.2.1. Market size and forecast
4.3.3.2.1.1. Fibrin-based sealants
4.3.3.2.1.2. Collagen-based sealants
4.3.3.2.1.3. Synthetic adhesives/glues
4.3.3.3. Market by anti-infective dressing
4.3.3.3.1. Market size and forecast
4.4. TRADITIONAL/BASIC WOUND CARE
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.3.1. Medical tapes
4.4.3.1.1. Market size and forecast
4.4.3.2. Dressings
4.4.3.2.1. Market size and forecast
4.4.3.3. Cleansing agents
4.4.3.3.1. Market size and forecast
CHAPTER 5 PHILIPPINES WOUND CARE MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. CHRONIC WOUNDS
5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size and forecast
5.2.3.1. Pressure ulcers
5.2.3.1.1. Market size and forecast
5.2.3.2. Diabetic foot ulcers
5.2.3.2.1. Market size and forecast
5.2.3.3. Venous leg ulcers
5.2.3.3.1. Market size and forecast
5.2.3.4. Arterial ulcers
5.2.3.4.1. Market size and forecast
5.3. ACUTE WOUNDS
5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size and forecast
5.3.3.1. Burns & trauma
5.3.3.1.1. Market size and forecast
5.3.3.2. Surgical wounds
5.3.3.2.1. Market size and forecast
CHAPTER 6 PHILIPPINES WOUND CARE MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. COMMUNITY HEALTH SERVICE CENTERS
6.3.1. Market size and forecast
CHAPTER 7 PHILIPPINES WOUND CARE MARKET, BY COUNTRY
7.1. PHILIPPINES
7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
CHAPTER 8 COMPANY PROFILES
8.1. 3M COMPANY
8.1.1. Company overview
8.1.2. Operating business segments
8.1.3. Product portfolio
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. ACELITY L.P. INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ALLIQUA BIOMEDICAL, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. B. BRAUN MELSUNGEN AG
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business Performance
8.4.6. Key strategic moves and developments
8.5. BSN MEDICAL GMBH
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. COLOPLAST A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. CONVATEC HEALTHCARE B S..R.L.
8.7.1. Company overview
8.7.2. Operating business segments
8.7.3. Product portfolio
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. INTEGRA LIFESCIENCES HOLDINGS CORPORATION
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. LOHMANN & RAUSCHER GMBH & CO. KG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Key strategic moves and developments
8.10. MEBO CHINA (A DIVISION OF MEBO INTERNATIONAL)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.11. MEDTRONIC PLC
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Business performance
8.11.6. Key strategic moves and developments
8.12. MLNLYCKE HEALTH CARE AB (A SUBSIDIARY OF INVESTOR AB)
8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Product portfolio
8.12.5. Business performance
8.13. MUNDIPHARMA INTERNATIONAL LIMITED
8.13.1. Company overview
8.13.2. Company snapshot
8.13.3. Operating business segments
8.13.4. Product portfolio
8.14. SMITH & NEPHEW PLC
8.14.1. Company overview
8.14.2. Operating business segments
8.14.3. Product portfolio
8.14.4. Business performance
8.14.5. Key strategic moves and developments
8.15. URGO MEDICAL (A DIVISION OF URGO GROUP)
8.15.1. Company overview
8.15.2. Company snapshot
8.15.3. Operating business segments